AgomAb Therapeutics NV
10.60%
5,141,992
2020932
00860C102
Feb 8, 2026
Feb 17, 2026, 07:00 AM
Reporting Persons (2)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| LSP 7 Cooperatieve U.A. | Other | 10.60% | 5,141,992 | 0 | 5,141,992 |
| LSP 7 Management B.V. | Other | 10.60% | 5,141,992 | 0 | 5,141,992 |
Disclosure Items (7)
Common Shares, no nominal value per share ("Common Shares")
AgomAb Therapeutics NV
Posthoflei 1/6, Antwerpen, C9, 2600
The Schedule 13D is being filed by the following persons (each a "Reporting Person" and, collectively, the "Reporting Persons"): LSP 7 Cooperatieve U.A. ("LSP 7"); and LSP 7 Management B.V. The managing directors of LSP 7 Management B.V. are Martijn Kleijwegt, Rene Kuijten and Joachim Rothe (collectively, the "Related Persons").
The business address of each of the Reporting Persons and the Related Persons is c/o LSP, Johannes Vermeerplein 9, 1071 DV Amsterdam, the Netherlands.
The Reporting Persons are principally engaged in the business of investments in securities. The current principal occupation of each of the Related Persons is Partner and Managing Director of EQT Life Sciences (formerly Life Sciences Partners).
During the last five years, none of the Reporting Persons nor any of the Related Persons was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
Each of the Reporting Persons is organized under the laws of the Netherlands. Messrs. Kleijwegt and Kuijten are citizens of the Netherlands, and Mr. Rothe is a citizen of Germany.
Prior to the Issuer's initial public offering (the "IPO"), LSP 7 purchased 185,585 shares of the Issuer's preferred stock in a series of transactions for aggregate consideration of approximately Euro 40 million. Upon the consummation of the IPO on February 9, 2026 (the "Closing Date"), the Issuer effected a 1-for-21.6450216450216 forward stock split of the Common Shares and all of LSP 7's preferred stock automatically converted into an aggregate 4,016,992 Common Shares. On the Closing Date, LSP 7 purchased 1,125,000 American Depositary Shares (each representing one Common Share) at a purchase price of $16.00 per share, for aggregate consideration of $18,000,000.00. LSP 7 obtained the funds for these transactions through capital contributions from its members.
The ownership information presented herein represents beneficial ownership of Common Shares as of the date hereof, based on 48,736,779 Common Shares outstanding as of February 9, 2026. LSP 7 is the record holder of the Common Shares reported herein and is the beneficial owner of approximately 10.6% of the outstanding Common Shares. LSP 7 Management B.V. is the sole director of LSP 7. The managing directors of LSP 7 Management B.V. are Martijn Kleijwegt, Rene Kuijten and Joachim Rothe.
Sole power to vote or to direct the vote: 0 Shared power to vote or to direct the vote: 5,141,992 Sole power to dispose or to direct the disposition of: 0 Shared power to dispose or to direct the disposition of: 5,141,992
Except as set forth in this Schedule 13D, during the past 60 days, none of the Reporting Persons nor the Related Persons have effected any transactions in the Common Stock.
None.
Not applicable.
Item 4 above summarizes certain provisions of the Shareholders' Agreement and the Lock-Up Agreement and is incorporated herein by reference. A copy of each such agreement is attached as an exhibit to this Schedule 13D and is incorporated by reference herein. Except as set forth herein, none of the Reporting Persons has any contracts, arrangements, understandings or relationships (legal or otherwise) with any person with respect to any securities of the Issuer, including but not limited to any contracts, arrangements, understandings or relationships concerning the transfer or voting of such securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or losses, or the giving or withholding of proxies.
Exhibit 1: Joint Filing Agreement Exhibit 2: Amended and Restated Shareholders' Agreement, dated as of November 4, 2024, by and among AgomAb Therapeutics NV and the shareholders party thereto (incorporated by reference to Exhibit 4.1 to the Issuer's Registration Statement on Form F-1 filed with the SEC on January 16, 2026). Exhibit 3: Form of Lock-Up Agreement (incorporated by reference to Exhibit 1.1. to the Issuer's Registration Statement on Form F-1 filed with the SEC on January 29, 2026).